Physician

Kent Marc-Josef Adler, M.D.

According to 2025 Medicare claims, Kent Adler, M.D. (NPI: 1013074632) practices medical oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is UCSF MEDICAL GROUP BUSINESS SERVICES (NPI: 1477624104; TIN: 943281660) and primary practice location at 94010-4145.

Adler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 257 traditional Medicare patients, billed 137,909 HCPCS/CPT codes, and received $3,188,653 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 649 prescription claims across 143 beneficiaries totaling $1,994,600 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 17 claims. Open Payments data shows 2 records totaling $38. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $838,883 to $3,188,653. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $696,550 to $1,994,600. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,858 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	405	46,502	$838,883
2016	415	63,644	$1,294,878
2017	360	48,880	$1,440,673
2018	383	73,880	$1,474,269
2019	369	61,248	$1,455,682
2020	271	53,474	$1,210,494
2021	245	52,656	$1,723,584
2022	292	88,454	$2,703,044
2023	295	101,574	$2,969,503
2024	257	137,909	$3,188,653

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	129	783	$696,550
2016	142	790	$587,148
2017	130	779	$894,906
2018	140	746	$1,024,196
2019	123	708	$1,285,592
2020	115	687	$1,347,799
2021	115	586	$698,418
2022	110	469	$888,157
2023	128	660	$1,585,053
2024	143	649	$1,994,600

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	36	$13,418
2016	12	83	$30,321
2017	N/R	82	$24,723
2018	N/R	156	$10,656
2019	N/R	82	$4,034
2020	N/R	13	$1,020
2021	N/R	N/R	N/R
2022	N/R	18	$937
2023	N/R	17	$1,289
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	123	297	$165
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	135	228	$113
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	78	173	$29
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	162	415	$15
J7030	Infusion, normal saline solution , 1000 cc	60	971	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	42	1,560	$884,479
Ibrance	Palbociclib	14	392	$226,211
Eliquis	Apixaban	30	1,865	$35,836
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	16	720	$4,244
Anastrozole	Anastrozole	96	7,670	$3,166

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$38	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kent Marc-Josef Adler, M.D.?

Tedicare shows public-source Medicare data for Kent Marc-Josef Adler, M.D. (NPI 1013074632), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kent Marc-Josef Adler, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kent Marc-Josef Adler, M.D.?

Kent Marc-Josef Adler, M.D. is linked to UCSF MEDICAL GROUP BUSINESS SERVICES (billing NPI 1477624104) in the available physician profile data.

Does Kent Marc-Josef Adler, M.D. have Open Payments data?

Kent Marc-Josef Adler, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.